Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Chidamide and Decitabine with R-CHOP in TP53-mutated/del(17p) DLBCL
NCT06750991Phase 2Not yet recruiting
- Sponsor
- Ruijin Hospital
- Start
- Dec 2024
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tucidinostat in diffuse large B-cell lymphoma (DLBCL), sponsored by Ruijin Hospital. Primary endpoint: Progression-free survival at 1 year. Planned start Dec 2024; status: not yet recruiting.
02
Drugs
tucidinostat
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT06750991.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06750991.